Afferent Pharmaceuticals Inc.
Targeting P2X3 for pain and other disorders
In drug development, the tiniest of targets sometimes prove windows of huge opportunity. For chronic pain start-up Afferent Pharmaceuticals Inc., a single receptor subfamily may hold the key to unlocking novel treatments for that tough-to-alleviate disorder and a remarkable number of other diseases.